Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Receivables: 2023-2024

Historic Change in Receivables for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $69.2 million.

  • Iovance Biotherapeutics' Change in Receivables fell 71.76% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 80.29%. This contributed to the annual value of $69.2 million for FY2024, which is 46335.57% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Change in Receivables stood at $69.2 million, which was up 46,335.57% from $149,000 recorded in FY2023.
  • Iovance Biotherapeutics' Change in Receivables' 5-year high stood at $69.2 million during FY2024, with a 5-year trough of $149,000 in FY2023.
  • In the last 2 years, Iovance Biotherapeutics' Change in Receivables had a median value of $34.7 million in 2023 and averaged $34.7 million.
  • Data for Iovance Biotherapeutics' Change in Receivables shows a peak YoY spiked of 46,335.57% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Change in Receivables (Yearly) stood at $149,000 in 2023, then surged by 46,335.57% to $69.2 million in 2024.